SAN JOSE, Calif., Dec. 12, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD FACSCelesta™ flow cytometer during the 2015 American Society for Cell Biology (ASCB) annual meeting. Uniquely designed to leverage the broad BD Horizon Brilliant™ reagent portfolio, this new system offers simultaneous measurement of up to 14 different single cell characteristics.
The BD FACSCelesta is an advanced system for driving scientific insights for a wide range of applications. Available now for research segment use, the BD FACSCelesta is the latest advancement in the award winning BD cell analyzer portfolio. It offers performance that is typically only seen in higher end systems, enabling consistency of results and seamless transfer of applications between BD platforms with 14 parameters in a three-laser benchtop system.
For more significant single cell studies and higher quality data, the BD FACSCelesta system opens new avenues of investigation and a deeper level of biological study. When combined with the patented technology of BD Horizon Brilliant™ polymer dyes, it enables greater resolution of previously unobserved cell populations and is an ideal solution for researchers wanting more fluorophore choices when using multicolor flow cytometry.
"Designed from the ground up, the BD FACSCelesta allows researchers to benefit from new innovations in instrument and reagent technology," said Claude Dartiguelongue, worldwide president of BD Biosciences. "This means that researchers can now, with improved brightness and low spectral overlap, optimally identify, characterize, and resolve even dim staining populations of interest."
The BD FACSCelesta flow cytometer is available in multiple configurations, delivering the performance required for varied immunology and cell biology applications. The system can help simplify experimental design and analysis for experienced researchers as well as those new to flow cytometry. The four configurations allow the use of 10 or 12 colors. The first live presentation will be held during the American Society for Cell Biology annual meeting held today through Dec. 16 at the San Diego Convention Center.
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com.
BD Public Relations
SOURCE BD (Becton, Dickinson and Company)